|
QMPSB
QMPSB is an arylsulfonamide-based synthetic cannabinoid that has been sold as a designer drug. QMPSB was first discovered by Nathalie Lambeng and colleagues in 2007. It acts as a full agonist of the CB1 receptor and CB2 receptor with Ki values of 3 nM and 4 nM, respectively. Many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive CB2 receptor. This work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004. The quinolin-8-yl ester motif of QMPSB led to the discovery of other designer cannabinoids such as PB-22 and BB-22. See also * 2F-QMPSB * 5F-PB-22 * FDU-PB-22 * FUB-PB-22 * NM-2201 * O-2050 * O-2113 * SDB-005 SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8- ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
2F-QMPSB
2F-QMPSB (SGT-13) is an arylsulfonamide-based synthetic cannabinoid that is a fluorinated derivative of QMPSB and has been sold as a designer drug. Its identification was first reported by a forensic laboratory in Italy in January 2019, and it was made illegal in Latvia shortly afterwards. Fluorination of the tail group is a common strategy to increase potency at cannabinoid receptors which is seen in many related series of compounds. See also * AZD1940 * FUB-PB-22 FUB-PB-22 (QUFUBIC) is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. Pharmacology FUB-PB-22 acts as a full agonist with a binding affinity of 0.386nM at CB1 and ... References Arylsulfonamides Cannabinoids Designer drugs Piperidines Quinolines {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
PB-22
PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013. PB-22 represents a structurally unique synthetic cannabinoid chemotype, since it contains an ester linker at the indole 3-position, rather than the precedented ketone of JWH-018 and its structural analog, analogs, or the amide of APICA (synthetic cannabinoid drug), APICA and its analogs. PB-22 has an EC50, EC50 of 5.1 nM for human CB1 receptors, and 37 nM for human CB2 receptors. PB-22 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, suggesting potent cannabinoid-like activity. The magnitude and duration of hypothermia induced in rats by PB-22 was notably greater than JWH-018, AM-2201, UR-144, XLR-11, APICA (synthetic cannabinoid drug), APICA, or STS-135 (drug), STS-135, with a reduction of body temperature still obse ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FUB-PB-22
FUB-PB-22 (QUFUBIC) is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. Pharmacology FUB-PB-22 acts as a full agonist with a binding affinity of 0.386nM at CB1 and 0.478nM at CB2 cannabinoid receptors. Legal status FUB-PB-22 is an Anlage II controlled substance in Germany. It was scheduled in Japan in July 2014. As of October 2015 FUB-PB-22 is a controlled substance in China. It is also banned in Sweden. See also * 2F-QMPSB * 5F-PB-22 * AM-2201 * BB-22 * FUB-JWH-018 * AB-FUBINACA * ADB-FUBINACA * AMB-FUBINACA * FDU-PB-22 * FUB-144 * FUB-APINACA * MDMB-FUBICA * MDMB-FUBINACA * PB-22 PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013. PB-22 represent ... References Cannabinoids Designer drugs Fluoroar ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Synthetic Cannabinoid
Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids (THC, CBD and many others) in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic phytocannabinoids (THC or CBD obtained by chemical synthesis) or synthetic endocannabinoids from which they are in many aspects distinct. Typically, synthetic cannabinoids are sprayed onto plant matter and are usually smoked, although they have also been ingested as a concentrated liquid form in the US and UK since 2016. They have been marketed as herbal incense, or "herbal smoking blends", and sold under common names like K2, spice, and synthetic marijuana. They are often labeled "not for human consumption" for liability defense. A large and complex variety of synthetic cannabinoids are designed in an attempt to avoid legal restrictions on cannabis, making synthetic cannabinoids designer drugs. Most synthetic cannabinoids are agonists o ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Designer Drugs
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects, and shorter duration (and possibly also because it is easier to apply for patents for new molecules) and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human trials, the use of some of these drugs may result i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cannabinoids
Cannabinoids () are several structural classes of compounds found in the cannabis plant primarily and most animal organisms (although insects lack such receptors) or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC) (delta-9-THC), the primary intoxicating compound in cannabis. Cannabidiol (CBD) is a major constituent of temperate Cannabis plants and a minor constituent in tropical varieties. At least 113 distinct phytocannabinoids have been isolated from cannabis, although only four (i.e., THCA, CBDA, CBCA and their common precursor CBGA) have been demonstrated to have a biogenetic origin. It was reported in 2020 that phytocannabinoids can be found in other plants such as rhododendron, licorice and liverwort, and earlier in Echinacea. Phytocannabinoids are multi-ring phenolic compounds structurally related to THC, but endocannabinoids are fatty acid derivatives. Nonclassical synthetic cannabinoids (cannabimimetics) include amin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
SDB-005
SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group. The code number SDB-005 was originally used for a different compound, the ''N''-phenyl instead of ''N''-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM). However, SDB-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in Europe as a designer drug, and was entered into the EMCDDA synthetic drug database under this name. Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005. See also * 5F-PB-22 * AM-2201 * BB-22 * JWH-018 * NM-2201 * NNE1 NNE1 (also known as N ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
O-2113
O-2113 is a drug that is a classical cannabinoid derivative, which acts as a potent agonist for cannabinoid receptors, producing sedation, hypothermia and analgesia in animal studies. See also * O-2050 * O-2372 * O-2545 O-2545 is an analgesic cannabinoid derivative created by Organix Inc. for use in scientific research. Unlike most cannabinoids discovered to date, it is water-soluble, which gives it considerable advantages over many related cannabinoids. It has ... References Benzochromenes Cannabinoids {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
O-2050
O-2050 is a drug that is a classical cannabinoid derivative, which acts as an antagonist for the CB1 receptor. This gives it an advantage in research over many commonly used cannabinoid antagonists, such as rimonabant, which at higher doses act as inverse agonists at CB1 as well as showing off-target effects. However, while O-2050 acts as a silent antagonist ''in vitro'', some tests ''in vivo'' have suggested it may show agonist activity under certain circumstances. See also * O-2113 O-2113 is a drug that is a classical cannabinoid derivative, which acts as a potent agonist for cannabinoid receptors, producing sedation, hypothermia and analgesia in animal studies. See also * O-2050 * O-2372 * O-2545 O-2545 is an analgesic ... References Alkyne derivatives Benzochromenes Cannabinoids CB1 receptor antagonists Phenols Sulfonamides {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
NM-2201
NM-2201 (also known as CBL-2201) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity. Pharmacology NM-2201 acts as a full agonist with a binding affinity of 0.332 nM at CB1 and 0.732 nM at CB2 cannabinoid receptors. It has been linked to serious adverse events in users. Legal status NM-2201 is specifically banned in Sweden, Germany (Anlage II), and Japan but is also controlled in many other jurisdictions under analogue laws. On May 30, 2018 the United States Drug Enforcement Administration, Department of Justice published a notice of intent to place NM-2201 and 4 other synthetic cannabinoids in schedule I of the Controlled Substances Act. This notice went into effect on June 29, 2018. Use NM-2201 was linked to an incident in December 2015 where 25-30 people in Ocala, FL were taken to hos ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FDU-PB-22
FDU-PB-22 is a derivative of JWH-018 that is presumed to be a potent agonist of the CB1 receptor, and has been sold online as a designer drug. Pharmacology FDU-PB-22 acts as a full agonist with a binding affinity of 1.19nM at CB1 and 2.43nM at CB2 cannabinoid receptors. Legal status FDU-PB-22 is a controlled substance in Germany and is banned in Japan and Sweden. See also * 5F-PB-22 * AM-2201 * BB-22 * FUB-JWH-018 * AB-FUBINACA * ADB-FUBINACA * AMB-FUBINACA * FUB-144 * FUB-APINACA * FUB-PB-22 * MDMB-FUBICA * MDMB-FUBINACA * PB-22 PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013. PB-22 represent ... References Designer drugs Fluoroarenes Naphthoylindoles Indolecarboxylates {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
